Alto Neuroscience (ANRO) Cash from Investing Activities (2023 - 2026)
Alto Neuroscience (ANRO) posted Cash from Investing Activities of -$556000.0 for Q1 2026, down 2216.67% sequentially from -$24000.0 in Q1 2025, and down 2216.67% YoY from $26267.7 in Q1 2025.
Alto Neuroscience (ANRO) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Cash from Investing Activities for 4 years, with the latest figure at -$556000.0 in Q1 2026.
- Quarterly Cash from Investing Activities fell 2216.67% year-over-year to -$556000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$556000.0 (up 70.35% YoY) and the FY2025 annual result came in at -$24000.0, up 98.84% from the prior year.
- Cash from Investing Activities retreated to -$556000.0 in Q1 2026 per ANRO's latest filing, from -$24000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$21000.0 in Q1 2023 and troughed at -$1.0 million in Q3 2024.
- A 4-year average of -$312500.0 and a median of -$282000.0 in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities plunged 2237.21% in 2024, then jumped 89.29% in 2025.
- Over 4 years, Cash from Investing Activities stood at -$352000.0 in 2023, then sank by 43.75% to -$506000.0 in 2024, then surged by 95.26% to -$24000.0 in 2025, then sank by 2216.67% to -$556000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$556000.0, -$24000.0, and -$506000.0 for Q1 2026, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -556,000.00 |
| Mar 31, 2026 | -556,000.00 |
| Mar 31, 2025 | -24,000.00 |
| Mar 31, 2025 | -24,000.00 |
| Dec 31, 2024 | -506,000.00 |
| Dec 31, 2024 | -506,000.00 |
| Sep 30, 2024 | -1.01 Mn |
| Sep 30, 2024 | -1.01 Mn |
| Jun 30, 2024 | -340,000.00 |
| Jun 30, 2024 | -340,000.00 |
| Mar 31, 2024 | -224,000.00 |
| Mar 31, 2024 | -224,000.00 |
| Dec 31, 2023 | -352,000.00 |
| Dec 31, 2023 | -352,000.00 |
| Sep 30, 2023 | -43,000.00 |
| Sep 30, 2023 | -43,000.00 |
| Jun 30, 2023 | -54,000.00 |
| Jun 30, 2023 | -54,000.00 |
| Mar 31, 2023 | -21,000.00 |
| Mar 31, 2023 | -21,000.00 |